← Product Code [DWJ](/productcode/DWJ) · K262089 # Disposable Warming Blanket (K262089) _Hangzhou Tappa Medical Technology Co., Ltd. · DWJ · Aug 21, 2026 · Cardiovascular · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K262089 ## Device Facts - **Applicant:** Hangzhou Tappa Medical Technology Co., Ltd. - **Product Code:** [DWJ](/productcode/DWJ.md) - **Decision Date:** Aug 21, 2026 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 870.5900 - **Device Class:** Class 2 - **Review Panel:** Cardiovascular - **Attributes:** Therapeutic, Pediatric ## Indications for Use The Disposable Warming Blanket is indicated for hypothermic patients or normothermic patients for whom induced hyperthermia or localized increase in temperature is clinically indicated. ## Device Story Disposable Warming Blanket; used in conjunction with Medical Warming Unit (K252861) to provide physical warming to patients. Device consists of non-woven fabric and PE film; functions by receiving thermal energy from the warming unit to regulate patient body temperature. Used in clinical settings; operated by healthcare professionals. Benefits include maintenance of normothermia or therapeutic warming for hypothermic patients. Output is physical heat transfer to the patient. ## Clinical Evidence No clinical data. Bench testing only, including performance testing (appearance, dimensions, welding strength), sterility, shelf-life (ASTM F1980), and biocompatibility (ISO 10993-1, -5, -10, -23). Combined use testing with the Medical Warming Unit was performed. ## Technological Characteristics Materials: Non-woven fabric and PE film. Dimensions: Various models ranging from 100x70cm to 210x100cm. Energy source: External (Medical Warming Unit). Sterilization: Available in sterile and non-sterile versions. Standards: ASTM F1886, F2096, F1929, F88, F1980; USP <71>; ISO 10993. ## Regulatory Identification A thermal regulating system is an external system consisting of a device that is placed in contact with the patient and a temperature controller for the device. The system is used to regulate patient temperature. ## Predicate Devices - IOB Warming Blankets ([K190221](/device/K190221.md)) ## Reference Devices - Medical Warming Unit ([K252861](/device/K252861.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} FDA U.S. FOOD & DRUG ADMINISTRATION Hangzhou Tappa Medical Technology Co., Ltd. Dan Cao Rm. 2002, Bldg. 1, Chutian Technology Bldg., # 225 Chutian Rd., Xixing St., Binjiang District, Hangzhou, Zhejiang, 310000, China Hangzhou, China Re: K262089 Trade/Device Name: Disposable Warming Blanket Regulation Number: 21 CFR 870.5900 Regulation Name: Thermal Regulating System Regulatory Class: Class II Product Code: DWJ Dated: June 21, 2026 Received: June 22, 2026 Dear Dan Cao: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K262089 - Dan Cao Page 2 Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). {2} K262089 - Dan Cao Page 3 Sincerely, # KATHLEEN M. GRUNDER -S for Nicole Gillette Assistant Director DHT2B: Division of Circulatory Support, Structural, and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K262089 | ? | | Please provide the device trade name(s). | | ? | | Disposable Warming Blanket | | | | Please provide your Indications for Use below. | | ? | | The Disposable Warming Blanket is indicated for hypothermic patients or normothermic patients for whom induced hyperthermia or localized increase in temperature is clinically indicated. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | | Please select the age group(s) for which the device(s) is to be used. | ☑ Neonates/Newborns (Birth to < 29 days old) ☑ Infants (29 days old to < 2 years old) ☑ Children (2 years old to < 12 years old) ☑ Adolescents (12 years old to < 22 years old) ☑ Adults (22 years old and greater) | ? | {4} K262089 # 510(k) Summary ## I. Submitter Hangzhou Tappa Medical Technology Co., Ltd. Room 2002, Building 1, Chutian Technology Building, No. 225 Chutian Road, Xixing Street, Binjiang District, Hangzhou, Zhejiang, 310000, China Contact person: Ms.Caodan Tel.:+86-13484165183 E-mail: caod@tongpumed.com Preparation date: June 11, 2026 ## II. Proposed Device Device Trade Name: Disposable Warming Blanket Common name: system, thermal regulating Regulation Number: 21 CFR 870.5900 Regulatory Class: Class II Product code: DWJ Review Panel: Cardiovascular ## III. Predicate Devices 510(k) Number: K190221 Trade name: IOB Warming Blankets Common name: System, thermal regulating Classification: Class II Product Code: DWJ Manufacturer IOB Medical Inc Page 1 of 5 {5} #### IV. Device description The Disposable Warming Blanket is indicated for hypothermic patients or normothermic patients for whom induced hyperthermia or localized increase in temperature is clinically indicated. Combined with Medical Warming Unit (K252861), the disposable warming blanket provides physical warming to the patient by controlling the temperature of the blanket, thereby assisting in regulating the patient's body temperature. #### V. Indications for use The Disposable Warming Blanket is indicated for hypothermic patients or normothermic patients for whom induced hyperthermia or localized increase in temperature is clinically indicated. #### VI. Comparison of technological characteristics with the predicate devices The comparison and discussion between the subject device and the predicate devices are listed in below table. Table1 General Comparison between Disposable Warming Blanket and the predicate device | Characteristics | Proposed device | Predicate device (K190221) | Discussion | | --- | --- | --- | --- | | Indications For Use | The Disposable Warming Blanket is indicated for hypothermic patients or normothermic patients for whom induced hyperthermia or localized increase in temperature is clinically indicated. | The IOB Warming Blankets are indicated for hypothermic patients or normothermic patients for whom induced hyperthermia or localized increase in temperature is clinically indicated. | Same | | Material Design | Consists of Non-woven fabric and PE film | Each blanket consists of two layers of non-woven polypropylene fabric coated with a layer of polyethylene. | Same | | Shelf Life | 5 years | 3 years | Difference 1 | | Sterility | Non-sterile and sterile | Non-sterile and sterile | Same | | Blanket | WB-1101-R/WB-1101-N | IOB-024 240cm×150cm | Similar | Page 2 of 5 {6} | Dimensions (approximate) | 210×100cm WB-1102-R/WB-1102-N 190X70cm WB-1103-R/WB-1103-N 200X100cm WB-1104-R/WB-1104-N 150X100cm WB-1105-R/WB-1105-N 130X100cm WB-1106-R/WB-1106-N 130X100cm WB-1105-R/WB-1107-N 190X100cm WB-1109-R/WB-1109-N 210X100cm WB-1110-R/WB-1110-N 210X100cm WB-1111-R/WB-1111-N 210X100cm WB-1113-R/WB-1113-N 210X100cm WB-1114-R/WB-1114-N 210X100cm WB-1115-R/WB-1115-N 210X100cm WB-2101-R/WB-2101-N 160X100cm WB-2102-R/WB-2102-N 100X70cm WB-1201-R/WB-1201-N | IOB-025 120cm×80cm IOB-026 150cm×120cm IOB-027 220cm×120cm IOB-028 100cm×100cm IOB-029 200cm×100cm IOB-301 170cm×100cm IOB-302 170cm×100cm IOB-303 180cm×120cm IOB-304 182cm×120cm | | | --- | --- | --- | --- | Page 3 of 5 {7} | | 210X100cm WB-1202-R/WB-1202-N 210X100cm WB-1203-R/WB-1203-N 180X100cm WB-1204-R/WB-1204-N 180X70cm WB-1205-R/WB-1205-N 210X100cm WB-1206-R/WB-1206-N 210X100cm WB-2201-R/WB-2201-N 100X90cm WB-2202-R/WB-2202-N 140X90cm | | | | --- | --- | --- | --- | # Analysis 1 The shelf life has been verified. This difference does not compromise safety or effectiveness. # VII. Non-Clinical Testing The device described in this summary was tested in accordance with applicable standards and internal performance specifications. The following tests were conducted, and the results met the acceptance criteria: # Performance testing: The following tests were conducted on the Disposable Warming Blanket: Appearance Dimensions Sterility Page 4 of 5 {8} Welding Strength In addition, combined use testing of the Medical Warming Unit and Disposable Warming Blanket was performed. # **Reprocessing, Sterility, and Shelf-Life** ASTM F1886/F1886M-16 ASTM F2096-11 ASTM F1929-23 ASTM F88/F88-23 USP<71> ASTM F 1980 # **Biocompatibility testing** Biocompatibility of the device was evaluated in accordance with the FDA guidance “Use of International Standard ISO 10993-1” The following testing was conducted: - ISO 10993-1 - ISO 10993-5 - ISO 10993-10 - ISO 10993-23 # **VIII. Clinical Testing** No clinical study is included in this submission. # **IX. Conclusion** The proposed device shares the same indications for use as the predicate device and has similar design features and technological characteristics. Performance testing data have demonstrated that the proposed device is as safe and as effective as the predicate device. Therefore, the proposed device is determined to be substantially equivalent to the predicate device. Page 5 of 5 --- **Source:** [https://fda-staging.innolitics.com/device/K262089](https://fda-staging.innolitics.com/device/K262089) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com